In Vitro activity of thiamphenicol against multiresistant Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in Italy

Journal of Chemotherapy

Volumn 14, Issue 6, 2002, Pages 554-561

  Marchese, A ^a   Debbia, E A ^b   Tonoli, E ^b   Gualco, L ^b   Schito, A M ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b NONE

Author keywords

Bactericidal activity; Chloramphenicol; Multiresistant pathogens; Phenicols; Post antibiotic effect; Thiamphenicol

Indexed keywords

AMOXICILLIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL DERIVATIVE; COTRIMOXAZOLE; ERYTHROMYCIN; IMIPENEM; PENICILLIN G; RIFAMPICIN; TETRACYCLINE; THIAMPHENICOL; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG POTENCY; DRUG TOLERABILITY; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; ITALY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE; STREPTOCOCCUS PNEUMONIAE;

EID: 0036969666     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2002.14.6.554     Document Type: Article

References (38)

1. Marchese A, Schito GC. Role of global surveillance in combating bacterial resistance. Drugs 2001; 61: 167-173.
2. Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infections is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47: 129-140.
3. Fridkin SK. Vancomycin-intermediate and resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001; 32:108-115.
4. Pallares R, Capdevila O, Grau I. Treatment options for resistant pneumococcal infections. Clin Microbiol Infect 1999; 5: 4S3-4S11.
5. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of Staphylococci with reduced susceptibility to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36: 1020-1027.
6. Marchese A, Mannelli S, Tonoli E, Gorlero F, Toni M, Schito GC. Prevalence of antimicrobial resistance in Streptococcus pneumoniae circulating in Italy: results of the Italian Epidemiological Observatory Survey (1997-1999). Microb Drug Res 2001; 7: 277-287.
7. Felmingham D, Grüneberg RN and The Alexander Project Group. The Alexander Project 19961997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45: 191-203.
8. Albini E, Belluco G, Berton M, Schiappacassi G, Ungheri D. In vitro antibacterial activity of thiamphenicol glycinate acetylcysteinate against respiratory pathogens. Drug Res 1999; 49; 6: 533-537.
9. Neu HC, Fu KP. In vitro activity of chloramphenicol and thiamphenicol analogs. Antimicrob Agents Chemother 1980; 18: 311-316.
10. Drago L, De Vecchi E, Fassina MC, Mombelli B, Tocalli L, Gismondo MR. Comparative in vitro activity of thiamphenicol-glycinate and thiamphenicol-glycinate acatylcysteinate and other antimicrobials against respiratory pathogens. Drug Res 2001; 51: 315-324.
11. Azzolini F, Gazzaniga A, Lodola E. Thiamphenicol excretion in subjects with renal insufficiency. Int J Clin Pharmacol 1970; 4: 303-308.
12. Azzolini F, Gazzaniga A, Lodola E, Natangelo R. Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver. Int J Clin Pharmacol 1972; 6: 130-134.
13. Drago L, De Vecchi E, Fassina MC, Mombelli B, Gismondo MR. Serum and lung levels of thiamphenicol after administration of its glycinate N-acetylcysteinate ester in experimentally infected guinea pigs. Int J Antimicrob Agents 2000; 13: 301-303.
14. Turton JA, Havard AC, Robinson S, et al. An assessment of chloramphenicol and thiamphenicol in the induction of aplastic anaemia in the BALB/c mouse. Food Chem Tox 2000; 38: 925-938.
15. Becker D, Katz J, Metz J. Comparative effects of thiamphenicol and chloramphenicol haemopoiesis and lymphocyte transformation in vitro in man. Postgrad Med J 1974; 50 (suppl 5): 88-94.
16. Manten A. Side effects of drugs. In: Dukes, MNG Ed. Vol.1-3,8 Excerpta Medica, Amsterdam, 1979.
17. Ferrari V. Salient features of thiamphenicol: review of clinical pharmacokinetics and toxicity. Sex Transm Dis 1984;11 (4 Suppl): 336-9.
18. Marchese A, Balistreri G, Tonoli E, Debbia EA, Schito GC. Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital. J Clin Microbiol 2000; 38: 866-869.
19. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Fourth Edition: Approved Standard M7-A4 (1997) and M100-S11 (2001). NCCLS, Wayne, PA.
20. Marchese A, Saverino D, Debbia EA, Pesce A, Schito GC. Antistaphylococcal activity of cefdinir, a new oral third-generation cephalosporin, alone and in combination with other antibiotics, at supra- and sub-MIC levels. J Antimicrob Chemother 1995; 35: 53-66.
21. Grassi C, De Benedetto F. Recent clinical evidence of the efficacy and safety of thiamphenicol glycinate acetylcysteinate and thiamphenicol glycinate. J Chemother 2002; 14, 3: 279-284.
22. Marca G, Mattina R, Dubini F, Cocuzza G. In vitro antibacterial activity of Sch 25393, a fluorinated analogue of thiamphenicol. J Antimicrob Chemother 1984; 13: 423-427.
23. Syriopoulou VP, Harding AL, Goldman DA, Smith AL. In vitro antibacterial activity of fluorinated analogs of chloramphenicol and thiamphenicol. Antimicrob Agents Chemother 1981; 19: 294-297.
24. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001; 163: 1730-1754.
25. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-382.
26. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH and The Canadian Community-acquired Pneumonia Working Group. Canadian Guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and The Canadian Thoracic Society. Clin Infect Dis 2000; 31: 383-421.
27. th edn., Williams & Wilkins, Baltimore, MD. 1996: 296-329.
28. Drago L, Fassina MC, Mombelli B, De Vecchi E, Lombardi A, Gismondo MR. Comparative effect of thiamphenicol glycinate, thiamphenicol glycinate N-acetylcysteinate, amoxicillin plus clavulanic acid, ceftriaxone and clarithromycin on pulmonary clearance of Haemophilus influenzae in an animal model. Chemotherapy 2000; 46: 275-281.
29. Rahell JJ, Simberkoff MS. Bactericidal and bacteriostatic action of chloramphenicol against meningeal pathogens. Antimicrob Agents Chemother 1979; 16:13-18.
30. Pèrez-Giraldo C, Rodriguez-Benito A. Moran FJ, Hurtado C, Blanco MT, Gomez-Gacia AC. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. J Antimicrob Chemother 1997; 39: 643-646.
31. Lombardi A, Drago L, De Vecchi E, Mombelli B, Gismondo MR. Antimicrobial activity of thiamphenicol-glycinate-acetylcysteinate and other drugs against Chlamydia pneumoniae. Drug Res 2001; 51: 264-267.
32. Todisco T, Eslami A, Baglioni S, Todisco C. An open, comparative pilot study of thiamphenicol glycinate hydrochloride vs clarithromycin in the treatment of acute lower respiratory tract infections due to Chlamydia pneumoniae. J Chemother 2002; 14, 3: 265-271.
33. Rice LB Tn 916 family conjugative transposons and dissemination of antimicrobial resistance determinants. Antimicrob Agents Chemother 1998; 42: 1817-1877.
34. Widdowson CA, Adrian P, Klugman KP. Acquisition of chloramphenicol resistance by the linearization and integration of the entire staphylococcal plasmid pC194 into the chromosome of Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44:393-395.
35. Novak R, Henriquest B, Charpentier E, Normark S, Tuomanen E. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 1999; 339: 589-593.
36. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois, Washington DC: American Society for Microbiology. 2001: Abs n° C1-1510.
37. Normark BH, Novak R, Örtqvist A, Kallenius G, Tuomanen E, Normark S. Clinical isolate of Streptococcus pneumoniae that exhibit tolerance of vancomycin. Clin Infect Dis 2001; 32: 552-558.
38. Rahman M. Alternatives to vancomycin in treating methicillin-resistant Staphylococcus aureus infections. J Antimicrob Chemother 1998; 41: 325-328.